Merseburger, A. S. Et Al. 2022. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.. The Lancet. Oncology , vol.23, no.11 , 1398-1408.

Merseburger, A. S., Attard, G., Åström, L., Matveev, V. B., Bracarda, S., Esen, A. A., ... Feyerabend, S.(2022). Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.. The Lancet. Oncology , vol.23, no.11, 1398-1408.

Merseburger, Axel Et Al. "Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.," The Lancet. Oncology , vol.23, no.11, 1398-1408, 2022

Merseburger, Axel S. Et Al. "Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.." The Lancet. Oncology , vol.23, no.11, pp.1398-1408, 2022

Merseburger, A. S. Et Al. (2022) . "Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.." The Lancet. Oncology , vol.23, no.11, pp.1398-1408.

@article{article, author={Axel S Merseburger Et Al. }, title={Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.}, journal={The Lancet. Oncology}, year=2022, pages={1398-1408} }